Questioning the cardioprotective action of hormone replacement therapy in postmenopausal women.
This article comments on the point of view by Rosano et al. and outlines that the only indications for hormone replacement therapy, at the lowest effective dose for the shortest possible time, should be limited to younger, recently menopausal women who are not at high risk for cardiovascular disease and with unsustainable menopausal symptoms, without any illusory attempt to prevent chronic diseases.